News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
548,743 Results
Type
Article (32258)
Company Profile (88)
Press Release (516397)
Multimedia
Podcasts (95)
Webinars (11)
Section
Business (167891)
Career Advice (1790)
Deals (31829)
Drug Delivery (76)
Drug Development (58722)
Employer Resources (115)
FDA (12283)
Job Trends (11745)
News (275986)
Policy (24197)
Tag
Academia (1906)
Academic (1)
Accelerated approval (7)
Adcomms (16)
Allergies (71)
Alliances (42558)
ALS (85)
Alzheimer's disease (1069)
Antibody-drug conjugate (ADC) (128)
Approvals (12344)
Artificial intelligence (290)
Autoimmune disease (24)
Automation (16)
Bankruptcy (247)
Best Places to Work (9268)
BIOSECURE Act (9)
Biosimilars (85)
Biotechnology (69)
Bladder cancer (82)
Brain cancer (29)
Breast cancer (290)
Cancer (2332)
Cardiovascular disease (171)
Career advice (1521)
Career pathing (25)
CAR-T (149)
CDC (22)
Cell therapy (424)
Cervical cancer (18)
Clinical research (48637)
Collaboration (907)
Company closure (1)
Compensation (338)
Complete response letters (13)
COVID-19 (1845)
CRISPR (49)
C-suite (275)
Cystic fibrosis (86)
Data (2483)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (282)
Diagnostics (4985)
Digital health (20)
Diversity (4)
Diversity, equity & inclusion (36)
Drug discovery (131)
Drug pricing (87)
Drug shortages (21)
Duchenne muscular dystrophy (101)
Earnings (73424)
Editorial (40)
Employer branding (14)
Employer resources (103)
Events (86599)
Executive appointments (710)
FDA (13610)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (8)
Funding (738)
Gene editing (100)
Generative AI (28)
Gene therapy (318)
GLP-1 (639)
Government (2950)
Grass and pollen (4)
Guidances (167)
Healthcare (14479)
HIV (36)
Huntington's disease (17)
IgA nephropathy (33)
Immunology and inflammation (121)
Immuno-oncology (9)
Indications (33)
Infectious disease (1965)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (46)
Intellectual property (96)
Interviews (311)
IPO (13335)
IRA (38)
Job creations (2881)
Job search strategy (1271)
Kidney cancer (10)
Labor market (31)
Layoffs (369)
Leadership (21)
Legal (6434)
Liver cancer (58)
Longevity (9)
Lung cancer (331)
Lymphoma (167)
Machine learning (5)
Management (39)
Manufacturing (318)
MASH (78)
Medical device (10164)
Medtech (10168)
Mergers & acquisitions (19200)
Metabolic disorders (674)
Multiple sclerosis (74)
NASH (13)
Neurodegenerative disease (83)
Neuropsychiatric disorders (28)
Neuroscience (1605)
NextGen: Class of 2025 (4986)
Non-profit (3488)
Now hiring (7)
Obesity (326)
Opinion (203)
Ovarian cancer (74)
Pain (80)
Pancreatic cancer (92)
Parkinson's disease (146)
Partnered (17)
Patents (229)
Patient recruitment (124)
Peanut (34)
People (45912)
Pharmaceutical (24)
Pharmacy benefit managers (12)
Phase I (14488)
Phase II (20964)
Phase III (16946)
Pipeline (1496)
Policy (145)
Postmarket research (2143)
Preclinical (6288)
Press Release (72)
Prostate cancer (132)
Psychedelics (29)
Radiopharmaceuticals (221)
Rare diseases (368)
Real estate (4305)
Recruiting (44)
Regulatory (16695)
Reports (37)
Research institute (1797)
Resumes & cover letters (283)
Rett syndrome (9)
RNA editing (6)
RSV (36)
Schizophrenia (80)
Series A (137)
Series B (81)
Service/supplier (4)
Sickle cell disease (49)
Special edition (13)
Spinal muscular atrophy (116)
Sponsored (24)
Startups (2591)
State (1)
Stomach cancer (10)
Supply chain (54)
Tariffs (41)
The Weekly (66)
Vaccines (560)
Venture capital (38)
Weight loss (203)
Women's health (30)
Worklife (13)
Date
Today (68)
Last 7 days (297)
Last 30 days (1515)
Last 365 days (25673)
2025 (14137)
2024 (27933)
2023 (31203)
2022 (40700)
2021 (43655)
2020 (42332)
2019 (36298)
2018 (27468)
2017 (25619)
2016 (24893)
2015 (29515)
2014 (24337)
2013 (20798)
2012 (21510)
2011 (21640)
2010 (20742)
Location
Africa (672)
Alabama (53)
Alaska (5)
Arizona (159)
Arkansas (9)
Asia (31007)
Australia (4903)
California (5708)
Canada (1858)
China (521)
Colorado (252)
Connecticut (281)
Delaware (152)
Europe (69912)
Florida (933)
Georgia (201)
Idaho (44)
Illinois (476)
India (24)
Indiana (295)
Iowa (12)
Japan (214)
Kansas (85)
Kentucky (19)
Louisiana (10)
Maine (62)
Maryland (748)
Massachusetts (4267)
Michigan (208)
Minnesota (317)
Mississippi (1)
Missouri (64)
Montana (24)
Nebraska (19)
Nevada (67)
New Hampshire (50)
New Jersey (2114)
New Mexico (18)
New York (1601)
North Carolina (885)
North Dakota (6)
Northern California (2532)
Ohio (184)
Oklahoma (14)
Oregon (24)
Pennsylvania (1238)
Puerto Rico (12)
Rhode Island (27)
South America (959)
South Carolina (26)
Southern California (2140)
Tennessee (112)
Texas (836)
United States (21852)
Utah (185)
Virginia (142)
Washington D.C. (55)
Washington State (500)
West Virginia (3)
Wisconsin (57)
548,743 Results for "alza corporation acquired by j and j".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cell therapy
J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study
Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gilead’s Yescarta.
June 16, 2025
·
2 min read
·
Tristan Manalac
Cell therapy
Gilead Gears Up To Challenge J&J in $20B Multiple Myeloma CAR -T Market
J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at least as good efficacy.
June 4, 2025
·
5 min read
·
Nick Paul Taylor
Approvals
J&J Steps Into Crowded Myasthenia Gravis Market With FDA Nod
With Imaavy, J&J will go toe-to-toe with fellow Big Pharma AstraZeneca, which owns Soliris and Ultomiris.
May 1, 2025
·
2 min read
·
Tristan Manalac
FDA
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.
March 21, 2025
·
2 min read
·
Tristan Manalac
Tariffs
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing
In the company’s first-quarter earnings call Tuesday, J&J CEO Joaquin Duato said there’s a better way to encourage drug manufacturing in the U.S. than President Donald Trump’s threatened pharma tariffs.
April 15, 2025
·
3 min read
·
Annalee Armstrong
Earnings
J&J Targets $50B Oncology Sales By 2030: Updated
Johnson & Johnson’s $23.7 billion in second-quarter earnings, driven by cancer and neuroscience drugs, exceeded analyst expectations, while CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030.
July 16, 2025
·
2 min read
·
Nick Paul Taylor
Earnings
J&J Beats Q1 Analyst Estimates Thanks To Tremfya, Carvykti, While Stelara Fades
J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the remaining $8 billion.
April 15, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR
June 30, 2025
·
6 min read
Depression
J&J Axes Late-Stage Depression Trial After Underwhelming Efficacy
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly given its recent $14.6 billion acquisition of Intra-Cellular Therapeutics and the success of Spravato for treatment-resistant depression.
March 7, 2025
·
2 min read
·
Tristan Manalac
Complete response letters
J&J’s FDA Bid for Subcutaneous Rybrevant Falls Short
The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with the regulator to resolve these problems.
December 17, 2024
·
2 min read
·
Tristan Manalac
1 of 54,875
Next